Short Interest in Rallybio Corporation (NASDAQ:RLYB) Drops By 62.7%

Rallybio Corporation (NASDAQ:RLYB) was the target of a significant decline in short interest during the month of July. As of July 31st, there was short interest totaling 63,485 shares, a decline of 62.7% from the July 15th total of 170,156 shares. Based on an average daily trading volume, of 30,844 shares, the days-to-cover ratio is currently 2.1 days. Currently, 1.3% of the shares of the company are sold short.

Rallybio Trading Up 0.2%

RLYB traded up $0.03 on Friday, hitting $16.99. 12,921 shares of the stock traded hands, compared to its average volume of 29,170. The business has a fifty day moving average price of $16.09 and a two-hundred day moving average price of $11.80. The firm has a market capitalization of $90.22 million, a PE ratio of -3.91 and a beta of -0.90. Rallybio has a 52 week low of $3.67 and a 52 week high of $17.57.

Rallybio (NASDAQ:RLYB) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($1.09) EPS for the quarter, topping analysts’ consensus estimates of ($1.28) by $0.19. Rallybio had a negative return on equity of 40.53% and a negative net margin of 911.07%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on RLYB. Wall Street Zen raised shares of Rallybio from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rallybio in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Rallybio presently has a consensus rating of “Sell”.

Insider Buying and Selling at Rallybio

In other news, major shareholder Adar1 Capital Management, Llc acquired 10,200 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The stock was acquired at an average cost of $13.98 per share, with a total value of $142,596.00. Following the acquisition, the insider owned 926,352 shares in the company, valued at approximately $12,950,400.96. This represents a 1.11% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Citadel Advisors LLC increased its holdings in Rallybio by 576.1% in the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after buying an additional 373,821 shares during the period. Susquehanna International Group LLP lifted its holdings in shares of Rallybio by 485.9% during the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after acquiring an additional 113,031 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Rallybio by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after acquiring an additional 2,996 shares during the period. Renaissance Technologies LLC boosted its position in shares of Rallybio by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after acquiring an additional 120,892 shares in the last quarter. Finally, XTX Topco Ltd boosted its position in shares of Rallybio by 64.6% during the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after acquiring an additional 38,205 shares in the last quarter. 90.34% of the stock is owned by institutional investors.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.